Literature DB >> 21722682

Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.

Elke S Bergmann-Leitner1, Patricia M Legler, Tatyana Savranskaya, Christian F Ockenhouse, Evelina Angov.   

Abstract

The malarial protein CelTOS, for cell-traversal protein for ookinetes and sporozoites, from Plasmodium berghei has been shown to mediate malarial invasion of both vertebrate and insect host cells and is required for establishing their successful infections. In the vertebrate host, Plasmodium sporozoites traverse via a complex passage through cellular barriers in the skin and the liver sinusoid to infect hepatocytes. Induction of immunity targeted to molecules involved in sporozoite motility and migration into hepatocytes may lead to abrogation of hepatocyte infection. We have previously demonstrated the potential of CelTOS as a target antigen for a pre-erythrocytic vaccine. The objective of the current study was to determine the potency of different vaccine platforms to induce protective immunity and determine the mode of action in protective immune responses. To this end, inbred Balb/c and outbred ICR mice were immunized with either the recombinant protein adjuvanted with Montanide ISA-720 or with a pCI-TPA plasmid encoding the P. berghei CelTOS (epidermal delivery by gene-gun) and assessed for the induction of protective responses against a homologous P. berghei challenge. Humoral and cellular immune responses induced by the various immunization regimens were evaluated in an effort to establish immune correlates. The results confirm that the CelTOS antigen is a potentially interesting pre-erythrocytic vaccine candidate and demonstrate that both arms of the adaptive immune system are required to mediate complete sterile protection against sporozoite challenge.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722682     DOI: 10.1016/j.vaccine.2011.06.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.

Authors:  Sakineh Pirahmadi; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Abbas-Ali Raz; Jafar J Sani
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

2.  Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites.

Authors:  Satish Mishra; Urvashi Rai; Takayuki Shiratsuchi; Xiangming Li; Yannick Vanloubbeeck; Joe Cohen; Ruth S Nussenzweig; Elizabeth A Winzeler; Moriya Tsuji; Victor Nussenzweig
Journal:  Vaccine       Date:  2011-07-30       Impact factor: 3.641

3.  Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.

Authors:  Christopher B Fox; Susan L Baldwin; Thomas S Vedvick; Evelina Angov; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2012-08-15

Review 4.  Progress towards the development of a P. vivax vaccine.

Authors:  Sai Lata De; Francis B Ntumngia; Justin Nicholas; John H Adams
Journal:  Expert Rev Vaccines       Date:  2021-03-04       Impact factor: 5.217

5.  Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults.

Authors:  Dorothy Anum; Kwadwo A Kusi; Harini Ganeshan; Michael R Hollingdale; Michael F Ofori; Kwadwo A Koram; Ben A Gyan; Susan Adu-Amankwah; Edem Badji; Jun Huang; Maria Belmonte; Glenna J Banania; Theophilus B Kwofie; Eileen Villasante; Daniel Dodoo; Martha Sedegah
Journal:  Malar J       Date:  2015-01-21       Impact factor: 2.979

6.  Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development.

Authors:  Joao C Aguiar; Jessica Bolton; Joyce Wanga; John B Sacci; Hideyuki Iriko; Julie K Mazeika; Eun-Taek Han; Keith Limbach; Noelle B Patterson; Martha Sedegah; Ann-Marie Cruz; Takafumi Tsuboi; Stephen L Hoffman; Daniel Carucci; Michael R Hollingdale; Eileen D Villasante; Thomas L Richie
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

7.  Novel insights from the Plasmodium falciparum sporozoite-specific proteome by probabilistic integration of 26 studies.

Authors:  Lisette Meerstein-Kessel; Jeron Venhuizen; Daniel Garza; Nicholas I Proellochs; Emma J Vos; Joshua M Obiero; Philip L Felgner; Robert W Sauerwein; Marynthe Peters; Annie S P Yang; Martijn A Huynen
Journal:  PLoS Comput Biol       Date:  2021-04-30       Impact factor: 4.475

8.  Role of host cell traversal by the malaria sporozoite during liver infection.

Authors:  Joana Tavares; Pauline Formaglio; Sabine Thiberge; Elodie Mordelet; Nico Van Rooijen; Alexander Medvinsky; Robert Ménard; Rogerio Amino
Journal:  J Exp Med       Date:  2013-04-22       Impact factor: 14.307

9.  Computational and experimental validation of B and T-cell epitopes of the in vivo immune response to a novel malarial antigen.

Authors:  Elke S Bergmann-Leitner; Sidhartha Chaudhury; Nicholas J Steers; Mark Sabato; Vito Delvecchio; Anders S Wallqvist; Christian F Ockenhouse; Evelina Angov
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

10.  Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malaria.

Authors:  Elke S Bergmann-Leitner; Heather Hosie; Jessica Trichilo; Elizabeth Deriso; Ryan T Ranallo; Timothy Alefantis; Tatyana Savranskaya; Paul Grewal; Christian F Ockenhouse; Malabi M Venkatesan; Vito G Delvecchio; Evelina Angov
Journal:  Front Immunol       Date:  2013-07-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.